The acquisition doubles Avantor's single-use cleanroom capacity to meet bioprocessing demand
Avantor, a global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, has acquired a China-based manufacturer of single-use bioprocess bags and assemblies for biopharmaceutical manufacturing applications, RIM Bio.
RIM Bio's Changzhou, China, facility is Avantor's first single-use production plant in the AMEA region, building on the company's existing global single-use manufacturing network in the Americas and Europe and doubles Avantor's global single-use cleanroom space to meet growing global demand in bioprocessing. Avantor will leverage RIM Bio's proprietary technologies and best-in-class lead times to provide single-use customers with a differentiated offering.
The acquisition doubles Avantor's single-use cleanroom capacity to meet bioprocessing demand
Dr Ger Brophy, Executive VP of Biopharma Production at Avantor, said: "Adding RIM Bio enables Avantor to better serve our customers by expanding our single-use manufacturing, distribution, and cleanroom capabilities to the AMEA region. RIM serves as an anchor for us to build our presence in this key region, as we better position Avantor to capture long-term opportunities in the growing, global Bioproduction space."
Established in 2009, RIM Bio provides a complete range of single-use 2D bags, 3D bags, tank liners, bag assemblies and multi-bag manifolds used in the manufacturing of biologics including monoclonal antibodies (mAbs), vaccines, cell and gene therapies, and recombinant proteins.
This acquisition marks another major investment in China. In December 2019, the company opened its Shanghai Innovation & Customer Support centre, a dedicated bioprocessing facility focused on research, application development and process optimisation solutions for biopharma companies across AMEA.